CA7800871021 - Common Stock
ROYAL BANK OF CANADA
NYSE:RY (12/20/2024, 8:04:00 PM)
After market: 120.72 0 (0%)120.72
+1 (+0.84%)
Royal Bank of Canada engages in the provision of banking and financial services. The company is headquartered in Toronto, Ontario and currently employs 96,165 full-time employees. Its business includes Personal & Commercial Banking, Wealth Management, Investor Services, Capital Markets and Insurance. The Personal & Commercial Banking comprises its personal banking operations and certain retail investment businesses in Canada, the Caribbean and United States, as well as its commercial and corporate banking operations in Canada and the Caribbean. Wealth Management provides a full suite of investment, trust and other wealth management solutions and businesses. Capital Markets provides public and private companies, institutional investors, governments and central banks globally with a range of capital markets products and services across its two main business lines, Corporate and Investment Banking and Global Markets. Insurance offers a range of life, health, home, auto, travel, wealth and reinsurance advice and solutions, and creditor and business insurance services to individual, business and group clients.
ROYAL BANK OF CANADA
Royal Bank Plaza, 200 Bay Street
TORONTO ONTARIO M5J2J5
P: 12124379267
CEO: David I. McKay
Employees: 96165
Website: https://www.rbcroyalbank.com/
Investors seeking AI plays may want to consider humanoid robots, which some analysts expect to begin replacing human workers at scale by the end of the decade.
RBC Capital lowered the firm’s price target on Lennar (LEN) to $130 from $160 and keeps an Underperform rating on the shares after its Q4 earnings miss and below-consensus guidance. The firm warns that material gross margin improvement for Lennar will remain elusive given “higher for longer” interest rates and the management remaining steadfast in its focus on aggressive volume targets using gross margins as a lever, the analyst tells investors in a research note. RBC also notes the potential fo
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $10 and keeps an Outperform rating on the shares. The company’s pipeline update to prioritize PYX-201 over further investment in PYX-106 is “prudent” given the early signs of activity and the operating expense savings that will be leveraged to continue to advance PYX-201 development, though the firm is reducing its price target on lower “pipeline optionality”, the analyst tells investors in a
Venture Global has applied to list its class A common stock on NYSE under the symbol "VG", according to a company filing on Friday.
How to invest when stocks are at all-time highs.
Here you can normally see the latest stock twits on RY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: